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Background: The beneficial effects of omega-3 polyunsaturated fatty acids (n-3 PUFAs), especially in dyslipidemic
subjects with a high risk of cardiovascular disease, are widely described in the literature. A lot of effects of n-3
PUFAs and their oxidized metabolites are triggered by regulating the expression of genes. Currently, it is uncertain
if the administration of n-3 PUFAs results in different expression changes of genes related to antioxidative
mechanisms in normo- and dyslipidemic subjects, which may partly explain their cardioprotective effects. The aim
of this study was to investigate the effects of n-3 PUFA supplementation on expression changes of genes involved
in oxidative processes.
Methods: Ten normo- and ten dyslipidemic men were supplemented for twelve weeks with fish oil capsules,
providing 1.14 g docosahexaenoic acid and 1.56 g eicosapentaenoic acid. Gene expression levels were determined
by whole genome microarray analysis and quantitative real-time polymerase chain reaction (qRT-PCR).
Results: Using microarrays, we discovered an increased expression of antioxidative enzymes and a decreased
expression of pro-oxidative and tissue enzymes, such as cytochrome P450 enzymes and matrix metalloproteinases,
in both normo- and dyslipidemic men. An up-regulation of catalase and heme oxigenase 2 in both normo- and
dyslipidemic subjects and an up-regulation of cytochrome P450 enzyme 1A2 only in dyslipidemic subjects could be
observed by qRT-PCR analysis.
Conclusions: Supplementation of normo- and dyslipidemic subjects with n-3 PUFAs changed the expression of
genes related to oxidative processes, which may suggest antioxidative and potential cardioprotective effects of n-3
PUFAs. Further studies combining genetic and metabolic endpoints are needed to verify the regulative effects of
n-3 PUFAs in antioxidative gene expression to better understand their beneficial effects in health and disease
prevention.
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Cardiovascular disease (CVD) is the leading cause of mor-
bidity and mortality in Europe, and frequently appears in
subjects with disorders of lipid metabolism. Evidence of
an association between dyslipidemia and increased oxida-
tive stress [1,2], as well as between increased oxidative
stress and the pathogenesis of CVD, are given by many
studies [3-7]. These associations indicate that dyslipidemia
increases oxidative stress, and thus promotes the patho-
genesis of CVD.
Enhanced oxidative stress results from either an over-
production of reactive oxygen species (ROS) or a
decreased antioxidative defence system. The most import-
ant ROS producers are nicotinamide adenine dinucleotide
phosphate oxidase [8], xanthine oxidase [9], uncoupled
endothelial nitric oxide synthase [10], and enzymes of the
arachidonic acid (AA, 20:4n-6) metabolism and the mito-
chondria [11]. The consequences of an increased ROS
production in CVD are vascular cell dysfunction [12],
increased growth of the myocard, apoptosis [13], and car-
diac remodelling via activation of matrix metalloprotei-
nases (MMP) [14].
The human body possess enzymatic and non-enzymatic
strategies to compensate oxidative damage and protect it-
self against such cytotoxic effects. Important antioxidative
enzymes include catalase (CAT), superoxide dismutase
(SOD), heme oxygenase (HMOX), and glutathione perox-
idase (GPX). Non-enzymatic antioxidants, such as gluta-
thione, ascorbate and α-tocopherol, are also important
regulators of the oxidative status. In the last few decades,
numerous observational and intervention studies have
shown the beneficial effects of fish oil (FO) and its princi-
pal omega-3 polyunsaturated fatty acids (n-3 PUFAs), ei-
cosapentaenoic acid (EPA, 20:5n-3) and docosahexaenoic
acid (DHA, 22:6n-3), in the prevention of atherosclerosis
and CVD [15-17]. Beyond the beneficial effects of n-3
PUFAs on the lipid profile [18-20], especially in subjects
with hypertriglyceridemia [21-23], n-3 PUFAs appear to
increase antioxidative capacity and thus reduce oxidative
stress [24,25]. However, the effects of n-3 PUFAs on oxi-
dative stress have not been studied in detail and some
existing results are inconsistent. Investigations in patients
with chronic renal failure showed reduced oxidative stress
after n-3 PUFA supplementation [24]. Furthermore,
in vitro studies with human aortic endothelial and HepG2
cells also determined reduced oxidative stress after n-3
PUFA treatment [25]. However, an indication of increased
oxidative stress in healthy judo athletes after n-3 PUFA
supplementation was observed [26]. The underlying mo-
lecular mechanisms by which EPA and DHA influence
oxidative stress are not completely understood. Changes
in expression levels of antioxidative genes in response to
FO supplementation have not been investigated in dyslipi-
demic subjects so far. In regard to the fact thatdyslipidemia increases oxidative stress and that dyslipi-
demic subjects possess a pro-oxidant status [27,28], we
hypothesised that n-3 PUFAs show their potential antioxi-
dative effects especially in dyslipidemic subjects. There-
fore, this intervention trial aimed to investigate the
expression changes of oxidative stress-related genes in
normo- and dyslipidemic subjects after FO supplementa-
tion to gain information about the potential antioxidative
effects of n-3 PUFAs.
Methods
This study focused on changes in oxidative stress-related
genes as part of a trial investigating the effects of FO
supplementation on whole-genome gene expression pro-
files in normo- and dyslipidemic men. The randomized,
controlled, parallel intervention study was conducted at
the Institute of Food Science and Human Nutrition at
the Leibniz University of Hannover in Germany, and
was designed and performed according to the principles
of the Good Clinical Practice Guidelines laid down in
the Declaration of Helsinki. It was approved by the Frei-
burg International Ethical Commission and registered at
ClinicalTrials.gov (ID: NCT01089231).
Subjects
Normo- and dyslipidemic men were recruited by several
advertisements and study placards in Hannover. The suit-
ability of volunteers was checked in telephone interviews
and by diet, lifestyle and disease questionnaires. Exclusion
criteria comprised smoking; body mass index> 35; intake
of any corticosteroids, lipid-lowering or anti-inflammatory
drugs; diagnosed chronically cardiovascular or liver dis-
eases; gastrointestinal disorders; blood coagulation disor-
ders and intake of coagulation-inhibiting drugs; renal
failure; periodic intake of laxatives; ingestion of supple-
ments enriched with n-3 PUFAs, phytosterols, polygluco-
samines, other lipid-binding ingredients or daily eating of
fatty fish; allergy to fish or FO; and participation in another
clinical study< 30 days before the start of the study or at
the same time. Selected subjects were invited for a screen-
ing examination to collect fasting blood and determine
serum lipid levels. Among these subjects, ten normolipi-
demic (total cholesterol (TC)< 200 mg/dl; low density
lipoprotein cholesterol (LDL-C)< 130 mg/dl; triacyltrigly-
ceride (TG)< 150 mg/dl) and ten dyslipidemic (TC>
200 mg/dl; LDL-C> 130 mg/dl; TG> 150 mg/ml) men,
aged between 29 and 51 years, were enrolled in the study
population. All participants included gave their written
informed consent to take part in the study. The study
protocol was approved by the Freiburger ethics committee.
Study design
The normo- and dyslipidemic subjects each ingested
six FO capsules per day for a period of twelve weeks.
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capsules was 2.7 g (1.14 g DHA and 1.56 g EPA). The
subjects were instructed to take the capsules together
with food, three in the morning and three in the even-
ing, and to maintain their usual exercise and dietary
habits throughout the intervention time. As an excep-
tion, on the first intervention day, all six capsules were
ingested at the same time in the morning after a stan-
dardised breakfast. Additionally, participants completed
a questionnaire to obtain information about changes in
medication, diet (e.g. changes in weekly fish intake,
preferred fish dishes or species, respectively) and life-
style habits (e.g. physical activity), as well as the toler-
ability of the capsules.Determination of red blood cell membrane fatty acid
composition
Fasting venous blood samples were collected into BD
VacutainerW Blood Collection Tubes (Becton Dickinson,
Heidelberg, Germany). Red blood cell (RBC) membrane
fatty acid (FA) composition, including the omega-3
index (EPA+DHA levels in RBC membranes), was ana-
lysed at baseline (t0) and after twelve weeks of supple-
mentation with FO (t12), according to the omega-3 index
methodology [29]. Accordingly, the RBCs were first
transesterificated, resulting in a generation of FA methyl
esters, followed by gas chromatography analysis using a
GC2010 Gas Chromatograph (Shimadzu, Freising, Ger-
many) equipped with a SP2560, 100 m column (Supelco,
Bellefonte, PA) using hydrogen as the carrier gas. Identi-
fication of the FAs was enabled by comparison with a
standard mixture of the FAs characteristic for RBCs.
The results are presented as a percentage of the total
FAs identified. The analytical coefficient of variation for
EPA and DHA was 5%. Quality was assured according
to DIN ISO 15189.Gene expression analyses
Sample collection
Fasting venous blood samples were collected in PAX-
gene Blood RNA Tubes (PreAnalytiX, Hombrechtikon,
Switzerland) at baseline (t0), after one week (t1) and after
twelve weeks (t12) of supplementation to analyse
medium- and long-term effects of the FO supplementa-
tion on gene expression regulation. For short-term
effects, venous blood samples were collected four hours
(t4h) after the first intake of the capsules. The whole
blood samples were collected and incubated for 24 hours
in the PAXgene Blood RNA Tubes at room temperature.
Whole blood samples were used for the RNA isolation
and examination of gene expression because cell frac-
tioning steps, such as lymphocyte isolation, could alter
the gene expression pattern [30].Total RNA isolation from human whole blood, RNA
purification and sample pooling
The total RNA was isolated with the PAXgene Blood
RNA Kit (PreAnalytiX, Hombrechtikon, Switzerland),
according to the manufacturer’s recommended proce-
dures. The RNA yield was quantified by Nanodrop ND-
1000 spectrophotometer (peQLab Biotechnologie GmbH,
Erlangen, Germany) measurement. The total RNA was
purified with the Globin Clear Kit (Ambion, Applied
Biosystems, Darmstadt, Germany), according to the
manufacturer’s instructions. The reduction of highly
abundant globin mRNA transcripts in whole blood
samples is necessary to enable the detection of low-
abundance transcripts [31]. The purified RNA was
quantified again, and the quality was measured with an
Agilent 2100 Bioanalyzer using RNA 6000 Nano Chips
and a RNA 6000 Nano Kit (Agilent Technologies,
Böblingen, Germany).
Equal amounts of purified RNA samples from each
member of the respective group were pooled together.
This was done for all different time points (t0, t4h, t1,
and t12). Therefore, four pool samples were generated by
this process for each group. The approach of sample
pooling was chosen to reduce biological inter-individual
variability, which is frequent due to variations in the
relative proportions of specific blood cell subsets, gen-
der, age, and disease state [32].
Microarray analysis (cDNA synthesis, hybridisation and data
analysis)
First-strand cDNA synthesis and tyramide signal amplifi-
cation (TSA) was performed using the Micromax TSA
Labelling and Detection Kit (Perkin Elmer Life Sciences,
Rodgau, Germany) with several protocol modifications.
A total amount of 6 μg from every RNA pool, as well as
random hexamer primer (Fermentas, St. Leon-Rot, Ger-
many) and oligo(dT) primer (Roth, Karlsruhe, Germany),
were used for the cDNA synthesis, which was facilitated
by using Superskript III reverse transcriptase (Invitrogen,
Karlsruhe, Germany). The incubation time of two hours
was split into two one-hour incubations and additional
Superskript III was added after the first hour. Each RNA
pool was synthesized into two differently labelled
cDNAs, fluorescein-labelled and biotin-labelled cDNA.
After labelling, the cDNA samples were purified with
the QIAquick PCR Purification Kit (Qiagen, Hilden,
Germany), according to the manufacturer’s instructions.
Furthermore, the cDNA samples were first vacuum-
dried and then resolved in hybridization buffer (4 x
SSPE; 2.5 x Denhardt’s reagent; 30% formamid). After a
final degradation step (3 minutes, 95°C), one-tenth of
top-block (Sigma-Aldrich, Steinheim, Germany) was
added. Equal amounts of biotin-labelled and fluorescein-
labelled cDNA were hybridized simultaneously in
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Microarrays (Phalanx Biotech Group; Belmont, CA,
USA). Hybridizations were carried out overnight at 42°C
in hybridization chambers (Eppendorf AG, Hamburg,
Germany). After hybridization, unbound and non-
specific fixed cDNA was removed by stringent washing
from the array. Specifically bound fluorescein- and
biotin-labelled cDNA were sequentially detected with a
series of conjugate reporter molecules according to the
TSA process, ultimately with tyramide-Cy3 and tyrami-
deCy5. Microarray experiments were performed for each
study group in a loop design to prevent dye-dependent
variety effects [33].
The array data were submitted to Gene Expression
Omnibus [34], which supports minimum information
about a microarray experiment [35]. The accession num-
ber of the submitted dataset is GSE34898. Genes that
were detected as differentially expressed between base-
line and time point t4h, t1 or t12 were subjected to path-
way analysis using the Kyoto Encyclopaedia of Genes
and Genomes (KEGG) database and GenMAPP [36].
Quantitative real-time polymerase chain reaction (qRT-PCR)
and data analysis
In order to quantify the expression levels of selected
genes, equal amounts of cDNA were synthesized using
2 μg of purified RNA and M-MLV reverse transcriptase
(Promega, Mannheim, Germany), as well as random
hexamer (Fermentas, St. Leon-Rot, Germany) and oligo
(dT) primers (Carl Roth; Karlsruhe, Germany). Synthe-
sized cDNA was diluted 1:20 with nuclease-free water
and used for the qRT-PCR together with iQ SYBR Green
Supermix (Bio-Rad Laboratories, Hercules, Ca, USA)
and 5 pmol of both forward and reverse primers. The
sequences for target and reference genes were retrieved
from GenBank and applied primers were manually
designed with the Primer-BLAST tool of the National
Centre for Biotechnology Information, which is based on
the program Primer3 [37]. The primer sequences used
are listed in Table 1. Glyceraldehyde-3-phosphate de-
hydrogenase (GAPDH) and ribosomal protein S2 (RPS2)
were identified as the most stable reference genes by the
freely available algorithm geNorm version 3.5.
Statistics
Statistical analysis of blood lipids and RBC membrane
FAs were processed with SPSS software version 20 (SPSS
Inc., Chicago, IL, USA). The results are based on per
protocol population, defined as subjects completing all
visits not infringing the study protocol, and are pre-
sented as mean± SD. Differences between baseline blood
lipid values of both groups were tested by t-test. Differ-
ences of FAs in RBC membranes between t0 and t12
were tested within groups by paired t-test. Statisticalsignificance was generally accepted at p ≤ 0.05. The
arrays were scanned with a 4000 B scanner (Axon
Instruments, Union City, CA, USA) and images were
quantified using GenePixPro 6.0 software for the statis-
tical analysis of the microarray data. The average pixel
intensity within each spot was determined and a local
background was computed for each spot. The net signal
was determined by subtracting local background from
the average intensity. Signals not consistently detectable
(background corrected signal lower than twice back-
ground standard deviation) were excluded from further
analysis. Following the primary analysis, data from dif-
ferent scans had to be summarized. The scans firstly had
to be normalized by the sum of all corresponding spot-
intensities due to different laser power and photomulti-
plier tube settings. Afterwards, data from different scans
for each individual spot could be averaged by the mean.
The mean of the data for differently labelled targets for
each gene on two microarrays was taken. In order to de-
duce if expression of a gene is significantly different in
the two samples, the preprocessed data was analyzed by
hypothesis testing. It was assumed that the distribution
of the preprocessed data was normal, and hence, a
standard two-state pooled-variance t-test (1% and 5%
probability of error) was applied in order to detect dif-
ferentially expressed genes. The genes can be categorized
into three groups using the calculated p-value of those t-
tests [1: slightly significant regulation (p = 0.05); 2: sig-
nificant regulation (p< 0.05); 3: highly significant regula-
tion (p< 0.01)].
Statistical analysis of the expression ratios of genes,
which were quantified by qRT-PCR, were calculated with
the Gene Expression Macro tool (Bio-Rad), which is
based on the algorithm of geNorm [38]. Firstly,
normalization factors were calculated from the geomet-
ric mean of the reference genes GAPDH and RPS2. Fur-
thermore, the baseline values of the normolipidemic
group were defined as control values so that relative ex-
pression values could be calculated. Therefore, the base-
line samples of the normolipidemic group are given a
value of 1. Due to the lack of Gene Expression Macro
tool to calculate statistics, differences between baseline
and endpoint (t12) Ct values were tested by paired t-test
using the statistical package R version 2.15.0.
Results
Subject characteristics
All 20 subjects (ten normolipidemic and ten dyslipidemic
men) completed the study. No significant differences of the
mean age and mean weight were observed between both
study groups at baseline. The dyslipidemic subjects pre-
sented a 4.47 kg/m² higher BMI, higher TC and TG level,
as well as a higher LDL-C/HDL-C quotient, than the nor-
molipidemic subjects (Table 2). Subjects of the dyslipidemic
Table 1 Nucleotide sequences of primers for quantitative real-time polymerase chain reaction
Gene symbol RefSeq_ID Sequences (5′-> 3′)
forward CTGACACTCACCGCCATCGCC
CAT NM_001752.2
reverse TGTCCTGCATGCACATCGGGC
NM_001127204.1
forward GCAGCAAGAACCACACCCAGCA
Target genes HMOX2 NM_001127205.1
NM_001127206.1
reverse TGGGTGTTTTCTGCCCGGTCG
NM_002134.3
forward AGCGCCGGTGTATCGGGGAAG
CYP1A2 NM_000761.3
reverse TCAGTTGATGGAGAAGCGCAGCCG
forward AAGGTGGTGAAGCAGGCGTCG
Reference genes GAPDH NM_002046.3
reverse AATGCCAGCCCCAGCGTCAAAG
forward GCAACTTCGCCAAGGCCACCTT
RPS2 NM_002952.3
reverse TGGGTCTTGACGAGGTGGTCAGT
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which is, among others, an underlying cause for dyslipide-
mia. The BMI was not changed by dietary intervention in
either study groups (data not shown).
Fatty acid composition of RBC membranes and omega-3
index
No significant differences of EPA or DHA levels in RBC
membranes or in the omega-3 index were observed be-
tween the study groups at baseline (Table 3). However, dys-
lipidemic subjects presented lower AA levels in RBC
membranes than normolipidemic subjects at baseline. The
percentage of EPA and DHA, and the omega-3 index inTable 2 Subjects characteristics of normo- and dyslipidemic m
Parameters No
Age [years] 36.
Height [cm] 180
Weight [kg] 77.
Body mass index (kg/m²] 23.
Total cholesterol [mg/dl] 183
Triacylglycerol [mg/dl] 82.
High density lipoprotein [mg/dl] 58.
Low density lipoprotein cholesterol [mg/dl] 108
LDL-C/HDL-C quotient 1.9
a t0 values of normolipidemic subjects vs. t0 values of dyslipidemic subjects were tRBC membranes significantly increased within both study
groups after twelve weeks of supplementation. Additionally,
the normolipidemic group showed a significant decrease of
the percentage of AA in RBC membranes.
Regulation of gene expression by n-3 PUFA
supplementation
It was necessary to exclude the RNA samples of one
normo- and three dyslipidemic subjects from the micro-
array experiments and following data analysis due to
several reasons: Low RNA yield (three subjects) and
consumption of medication that led to exclusion (one
subject). Therefore, RNA pools were generated and dataen at baseline (t0)
rmolipidemic (n = 9) Dyslipidemic (n = 7)
56 ± 8.00 41.43 ± 6.63
.61 ± 6.56 180.28 ± 8.62
41 ± 15.44 91.84 ± 12.83
66 ± 3.97 a 28.13 ± 1.99 a
.33 ± 13.88 a 272.86 ± 67.1 a
22 ± 37.42 a 362.00 ± 284.62 a
67 ± 10.92 45.86 ± 6.15
.33 ± 13.54 146.60 ± 6.43
0 ± 0.37 a 3.10 ± 0.47 a
ested by student’s t-test; p< 0.05.
Table 3 Red blood cell membrane fatty acid composition of normo- and dyslipidemic men at baseline (t0) and after
supplementation with fish oil over twelve weeks (t12)
Normolipidemic (n = 9) Dyslipidemic (n = 7)
Fatty acid [%]* t0 t12 t0 t12
C20:4n-6 (AA) 16.04 ± 0.80 a 13.09 ± 0.63 # 12.71 ± 2.52 a 11.56 ± 1.58
C20:5n-3 (EPA) 0.85 ± 0.20 3.85 ± 0.64 # 1.02 ± 0.43 3.46 ± 0.68 #
C22:6n-3 (DHA) 4.47 ± 0.67 6.92 ± 0.81 # 3.85 ± 1.45 6.46 ± 0.77 #
SFA 36.42 ± 1.46 39.24 ± 1.25 # 36.74 ± 1.78 39.24 ± 1.74
MUFA 17.98 ± 1.64 a 17.20 ± 1.02 b 22.15 ± 3.44 a 19.03 ± 1.18 b#
PUFA 44.59 ± 2.37 a 42.98 ± 1.16 # 40.13 ± 2.90 a 41.11 ± 1.71
n-3 PUFA 7.90 ± 0.94 14.71 ± 1.45 # 7.33 ± 2.04 13.53 ± 1.49 #
n-6 PUFA 36.68 ± 2.09 a 28.27 ± 1.39 # 32.80 ± 2.04 a 27.58 ± 1.86 #
Omega-3 index 5.32 ± 0.74 10.77 ± 1.10 # 4.87 ± 1.83 9.92 ± 1.34 #
* percentage of total fatty acids.
a t0 values of normolipidemic subjects vs. t0 values of dyslipidemic subjects were tested by student’s t-test; p< 0.05.
b t12 values of normolipidemic subjects vs. t12 values of dyslipidemic subjects were tested by student’s t-test; p< 0.05.
# t0 values vs. t12 values were tested by student’s paired t-test; p< 0.05.
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pidemic subjects for each investigation time point.
Microarray experiments showed that several genes
related to different oxidative processes were regulated.
These genes are listed with the respective regulation
ratio for each time point in Table 4. Several enzymes of
the glutathione metabolism are regulated after FO sup-
plementation, particularly in dyslipidemic subjects.
While genes related to the glutathione synthesis were
similarly up- and down-regulated during the first two
time points (t4h and t1), these genes were mainly up-
regulated after twelve weeks of FO supplementation.
Two different glutathione transferases (GST) and gluta-
thione reductase (GR) were up-regulated, whereas gluta-
thione peroxidases were down-regulated in both normo-
and dyslipidemic subjects. MMPs were down-regulated
in both normolipidemic (MMP25) and dyslipidemic sub-
jects (MMP2, MMP3) after twelve weeks of supplemen-
tation. Furthermore, cytochrome P450 (CYP) enzymes
were mainly down-regulated after twelve weeks of sup-
plementation, especially in dyslipidemic subjects. Add-
itionally, some antioxidative enzymes, such SOD3, CAT
and HMOX2, were up-regulated after twelve weeks of
supplementation in dyslipidemic subjects. Moreover,
pathway analysis discovered several regulated genes
within stress-activated signalling pathways, such as the
mitogen-activated protein kinase (MAPK) signalling
pathway, the nuclear factor kappa b (NFkB) pathway and
the oxidative stress athway (Additional file 1).
Several genes were selected for analyses of gene ex-
pression ratios by qRT-PCR, including the two antioxi-
dative enzymes, CAT and HMOX2, and CYP1A2
(Figure 1), a member of the CYP family known to be
involved in epoxidation of EPA and DHA [39]. The ex-
pression of HMOX2 was significantly up-regulated afterFO supplementation over a period of twelve weeks in
both normo- and dyslipidemic subjects (p=0.02 and
p=0.04). The expression of CAT was also up-regulated,
but reached significance only in normolipidemic subjects
(p=0.002). The expression of CYP1A2 was significantly
up-regulated only in dyslipidemic subjects (p=0.04). The
qRT-PCR results mainly confirm the microarray results
observed, whereupon differences in the strength of ex-
pression occur.
Discussion
To the best of our knowledge, this is the first interven-
tion study disclosing gene expression changes in normo-
and dyslipidemic subjects after FO supplementation. We
identified several genes involved in oxidative processes,
which were regulated by FO. The expression of antioxi-
dative enzymes was up-regulated particularly in dyslipi-
demic subjects, while the expression of pro-oxidative or
tissue damage-related enzymes was down-regulated. We
suggest that n-3 PUFAs may have an antioxidative
potential.
Antioxidative effects could be facilitated by either a
reduced production of ROS or an increased production
of antioxidative enzymes. Several human studies and
in vitro experiments showed reduced superoxide or ROS
production by monocytes and neutrophils after n-3
PUFA administration [40-42]. Additionally, negative cor-
relations between ROS production and n-3 PUFA mem-
brane content in healthy [40] and dyslipidemic subjects
[41] were observed. On the other hand, positive correla-
tions between the n-3 PUFA membrane content and the
activity of antioxidative enzymes could be investigated in
fibroblasts cell cultures [43] and in type 2 diabetes
patients [44]. In the present study, the supplementation
of normo- and dyslipidemic subjects with FO resulted in
Table 4 Ratios of differentially expressed genes related to oxidative processes
Regulated genes Gene
symbol
Entrez_ID RefSeq_ID Dyslipidemic Normolipidemic
Ratio t4h :
t0
Ratio t1 :
t0
Ratio t12 :
t0
Ratio t4h :
t0
Ratio t1 :
t0
Ratio t12 :
t0
Gluthatione metabolism
Glutathione peroxidase 1 GPX1 2876 NM_000581.2 - - - - - −2.48 3
NM_201397.1
Glutathione S-transferase Mu 3 GSTM3 2947 NM_000849.4 −2.30 1 4.12 2 2.47 2 - - -
Glutathione synthetase GSS 2937 NM_000178.2 −7.97 1 - - - - -
Phospholipid hydroperoxide
glutathione peroxidase,
mitochondrial
GPX4 2879 NM_001039848.1 - −3.74 1 - - - -
NM_001039847.1
NM_002085.3
Glutathione S-transferase P GSTP1 2950 NM_000852.3 - −2.00 2 - - - -
Gamma-glutamyltransferase 5 GGTLA1 2687 NM_001099782.1 3.44 1 14.90 1 7.98 1 - - -
NM_001099781.1
NM_004121.2
Glutathione peroxidase 3
(plasma)
GPX3 2878 NM_002084.3 - - −2.15 1 - - -
Glutathione reductase GSR 2936 NM_000637.2 - - 2.38 3 - - -
Matrix metalloproteinases
Matrix metalloproteinase-25 MMP25 64386 NM_022468.4 - - - 2.14 2 - −2.30 1
Metalloproteinase inhibitor 2 TIMP2 7077 NM_003255.4 - −4.18 1 −2.29 1 - - -
stromelysin-1 MMP3 4314 NM_002422.3 - - −2.17 1 - - -
72 kDa type IV collagenase MMP2 4313 NM_001127891.1 - −3.91 1 −6.16 1 - - -
NM_004530.4
Cytochrom P450 enzymes
Cytochrome P450 1A2 CYP1A2 1544 NM_000761.3 - - - - - −7.74 2
Cytochrome P450 2A7 CYP2A7 1548 NM_000762.5 - −2.46 1 - −2.42 1 −2.70 1
Cytochrome P450 4X1 CYP4X1 260293 NM_178033.1 - −5.66 1 −11.35 1 - - -
Cytochrome P450 26A1 CYP26A1 1592 NM_057157.2 2.87 1 - - - - -
NM_000783.3
Cytochrome P450 2B6 CYP2B6 1555 NM_000767.4 2.60 1 - - - - -
Cytochrome P450 4F12 CYP4F12 66002 NM_023944.3 2.46 1 - - - - -
Cholesterol side-chain cleavage
enzyme, mitochondrial
CYP11A1 1583 NM_001099773.1 −2.30 1 −2.78 1 −2.79 1 - - -
NM_000781.2
Cytochrome P450 26B1 CYP26B1 56603 NM_019885.2 −3.11 1 - - - - -
Cytochrome P450 2C19 CYP2C19 1557 NM_000769.1 −7.48 1 - - - - -
Steroid 17-alpha-hydroxylase/
17,20 lyase
CYP17A1 1586 NM_000102.3 −7.96 1 - −4.19 1 - - -
Cytochrome P450 2J2 CYP2J2 1573 NM_000775.2 - -3.54 1 - - - -
Cytochrome P450 27C1 CYP27C1 339761 NM_001001665.3 - −4.46 1 −3.41 1 - - -
Cytochrome P450 2A13 CYP2A13 1553 NM_000766.3 - −4.49 1 −8.90 1
Others
SOD3 6649 NM_003102.2 - - 4.70 3 - - 2.91 3
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Table 4 Ratios of differentially expressed genes related to oxidative processes (Continued)
Extracellular superoxide dismutase
[Cu-Zn]
Catalase CAT 847 NM_001752.2 - 13.15 1 8.90 1 - - -
Heme oxygenase 1 HMOX1 3162 NM_002133.1 - −8.57 1 −17.52 1 - - -
Heme oxygenase 2 HMOX2 3163 NM_001127204.1 - −11.44 1 7.84 1 - - -
NM_001127205.1
NM_001127206.1
NM_002134.3
Epoxide hydrolase 1 EPHX1 2052 NM_000120.3 - - 3.14 2 −2.24 2 - 2.22 2
NM_001136018.2
Arachidonate 5-lipoxygenase-
activating protein
ALOX5AP 241 NM_001629.2 - - 6.97 1 - - -
Nitric oxide synthase, endothelial NOS3 4846 NM_000603.4 - −4.22 1 −2.55 1 - - -
Nitric oxide synthase, inducible NOS2 4843 NM_000625.4 - −8.11 1 −4.77 1 - - -
Nitric oxide synthase-interacting
protein
NOSIP 51070 NM_015953.3 - - - - - 3.64 1
NADPH oxidase 1 NOX1 27035 NM_013955.2 - - 2.06 1 - - -
NM_007052.4
Expression ratios were displayed for genes which were differentially expressed after four hours (t4h), one week (t1) and twelve weeks (t12) of fish oil
supplementation in normolipidemic and dyslipidemic men.
- no regulation.
1 slightly significant regulation; p = 0.05.
2 significant regulation; p< 0.05.
3 highly significant regulation; p< 0.01.
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http://www.nutritionandmetabolism.com/content/9/1/45decreasing AA levels in RBC membranes in favour of
EPA and DHA, whose levels increased considerably. Ac-
cordingly, the increase of EPA and DHA levels observed
in RBC membranes together with an increased expres-
sion ratio of the antioxidative enzymes CAT and
HMOX2 are in agreement with the findings of BenitoFigure 1 Transcript levels of target genes in normo- and dyslipidemic
and cytochrome P450 enzyme 1 A2 (CYP1A2) was determined by qRT-PCR
(t12) of fish oil supplementation. Pooled group samples were used in triplic
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and ribosomal prote
gene expression of normolipidemic subjects and relative expression chang
values were tested by a paired t-test and differences between groups at ea[43] and Smaoui [44]. Moreover, the replacement of AA,
which is an important ROS producer, in biological mem-
branes may partly explain the antioxidative properties of
n-3 PUFAs. On the other hand, the incorporation of
EPA and DHA in RBC membranes in response to long-
term n-3 PUFA administration results in increasedmen. Transcript levels of catalase (CAT), heme oxygenase 2 (HMOX2)
in normo- and dyslipidemic men before (t0) and after twelve weeks
ates. Triplicates were averaged and corrected by two reference genes,
ine S2 (RPS2). Corrected expressions were compared with baseline
es are displayed. Differences between baseline and endpoint (t12) Ct
ch time point were tested by unpaired t-test.
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http://www.nutritionandmetabolism.com/content/9/1/45induced lipid peroxidation [45]. In this context, an activa-
tion of antioxidative gene expression in response to n-3
PUFA supplementation might be a reaction of the defence
system to lower lipid peroxidation. Complementary analysis
of oxidative damage or oxidative stress markers com-
bined with expression changes of anti- and pro-oxidant
genes should be used to indentify global antioxidative
effects.
Nevertheless, an increased expression of HMOX2 and
CAT in normo- and dyslipidemic subjects may indicate
some antioxidative effects of n-3 PUFAs. To our know-
ledge, this is the first study at all showing a regulation of
HMOX2 expression after n-3 PUFA supplementation in
humans. HMOXs are antioxidative enzymes which cata-
bolise heme to biliverdin and carbon monoxide. The two
existing HMOXs 1 and 2 differ in their activity. HMOX2
is constitutively expressed, whereas HMOX1 is indu-
cible, e.g. by cellular stress [46]. HMOX2 was identified
as part of the large-conductance calcium and voltage-
activated potassium (BK(Ca)) channel complex and
could enhance its activity, while knockdown of HMOX2
expression reduced channel activity [47]. BK(Ca) chan-
nels could influence the cell membrane potential and,
therefore, play an important role in many physiological
functions, including oxygen-sensing, neuronal excitabil-
ity, vascular tone regulation, and neurotransmitter re-
lease [48,49]. However, a possible clinical relevance of an
increased HMOX2 expression after FO supplementation
has to be clarified in further studies.
CAT is an effective antioxidative enzyme [50] known to
compensate H2O2 [51,52], e.g. in the centre of inflamma-
tion [53,54]. In this study, expression ratios of the micro-
array experiments showed an increased expression of CAT
in dyslipidemic subjects, whereas qRT-PCR showed an
increased expression in both study groups, reaching statis-
tical significance only in normolipidemic subjects. These
differences are also known from several other gene expres-
sion studies and are mainly explained by the greater sensi-
tivity of the qRT-PCR [55,56]. The increased expression of
CAT in normolipidemic subjects is in contrast to studies
with healthy volunteers, which mostly showed no effects on
CAT activity after FO supplementation [57,58]. Results
from animal studies, however, indicated an increased CAT
activity after treatment with n-3 PUFA [59,60]. Human
studies analysing the effects of n-3 PUFAs on the activity
or expression of CAT in dyslipidemic subjects are very
limited. In accordance with our results, Bouzidi and cow-
orkers [24] reported an increased CAT activity in patients
with dyslipidemia and chronic renal failure after n-3 PUFA
supplementation, assuming a greater protection against
oxidative stress and prevention of vascular complications.
Similarly, an animal study with hypercholesterolemic rats
also observed increased CAT activity after DHA feeding.
Taken together, these findings suggest that longtermsupplementation with n-3 PUFAs results in an enhanced
capacity to detoxify H2O2 and might induce adaptive
changes in the antioxidative defence system [61].
Glutathione is an important antioxidant which could
be readily oxidized non-enzymatically to glutathione di-
sulfide [62]. Most studies analysing the effects of n-3
PUFA supplementation on the activity of glutathione
metabolism related enzymes, such as GPX, gamma-
glutamylcysteine synthetase (gamma-GCL), GST, and
GR, in healthy and dyslipidemic subjects showed
increased activities of these enzymes [63-65]. In our
study, the expression of GST and GR was increased in
dyslipidemic subjects, while the expression of GPX was
decreased in both normo- and dyslipidemic subjects.
The increased expression of GST and GR is an indica-
tion of an increased glutathione synthesis and, therefore,
an increased antioxidative defence status. GPX is recog-
nized as an antioxidative enzyme which oxidizes gluta-
thione to reduce and detoxify H2O2. Consequently, this
enzyme is required when H2O2 levels rise in phases of
oxidative stress [66,67]. Therefore, a decreased expres-
sion of GPX - observed in this study - could be an indi-
cator of decreased oxidative stress. However, the results
in the literature are inconsistent. Mabile and co-workers
could not observe a change in the GPX activity in
healthy and hypertriglyceridemic subjects [68], while
other studies reported a stimulated GPX activity after n-
3 PUFA supplementation in healthy [63] and hyperlipid-
emic subjects [64]. Furthermore, it was shown that DHA
increased the activity of GST, gammaGCL and GR, as
well as the mRNA expression of gamma-GCL and GR
[65], in human fibroblasts, which is in agreement with
our results.
CYP enzymes catalyze the oxidation of xenobiotic sub-
stances, such as pharmaceuticals, but also metabolize many
endogenous substances, such as lipids and steroidal hor-
mones. Besides cyclooxygenases and lipoxygenases, CYPs
are also involved in the metabolism of PUFAs to form nu-
merous different oxidized FA metabolites, also named oxy-
lipines. The CYP isoforms of families 1 to 3 are mainly
epoxygenases, and CYP isoforms from family 4 are mainly
ω-hydroxylases [69]. In this study, several CYPs, mostly iso-
forms of family 2, were regulated after FO supplementation.
The oxidation of EPA and DHA by epoxygenases could
produce epoxy-derivates [70] and highly anti-inflammatory
resolvins and protectins [71].
Generated EPA and DHA epoxides are effective dila-
tors of coronary arterioles, facilitated by the activation of
calcium-activated potassium channels [72,73]. The qRT-
PCR showed that CYP1A2, which is one of the most ef-
ficient CYPs for the epoxidation of EPA and DHA in
human liver microsomes [39], was up-regulated in dysli-
pidemic subjects after FO supplementation, suggesting
the formation of specific EPA and DHA epoxides.
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http://www.nutritionandmetabolism.com/content/9/1/45Expression ratios of the microarray experiments showed
decreased expression of CYP1A2 in normolipidemic
subjects, which was, however, not confirmed by qRT-
PCR. According to qRT-PCR experiments, the expression
of CYP1A2 in normolipidemic subjects was not affected
by FO treatment. Both results are in contrast to micro-
array experiments, where CYP1A2 was unregulated in
dyslipidemic subjects and down-regulated in normolipi-
demic subjects. In view of the higher accuracy of qRT-
PCR, it is suggested that the microarray result for
CYP1A2 was false positive for normolipidemic subjects,
while the microarray technique was insensitive to analyse
the up-regulation of CYP1A2 in dyslipidemic subjects,
which was generally much weaker. Interestingly, human
liver microsomes, which were incubated with EPA and
DHA (200 μM) showed a decreased CYP1A2 activity [74].
Although the results are contradictory, it has been repeat-
edly shown that n-3 PUFAs could induce the expression
or activity of CYP enzymes, resulting in the formation of
EPA and DHA metabolites [39,69,70,74,75]. The complex
formation of n-3 PUFA metabolites by CYPs has not been
investigated systematically so far; however, it is likely that
the formation of these metabolites may explain numerous
of the anti-inflammatory and cardioprotective effects of n-
3 PUFAs [76].
MMPs are zinc-based proteases and could cleave macro-
molecules of the extra cellular matrix (ECM), e.g. collagens,
as well as non-ECM molecules, such as growth factors,
cytokines and their receptors [77]. ROS could induce the
activity of MMPs [78], which could result in tissue remod-
elling processes [79] and promote the pathogenesis of sev-
eral CVDs [80,81]. In this study, MMP2 and MMP3 in
dyslipidemic subjects and MMP25 in normolipidemic sub-
jects were down-regulated after FO supplementation. In ac-
cordance with our results, several other authors have
shown decreased MMP2 and/or MMP9 expression or ac-
tivity by n-3 PUFA in dyslipidemic subjects [82] and human
cell cultures [83,84]. However, no changes in MMP9 activ-
ity were detected after FO supplementation in patients with
coronary heart disease [85]. Similarly, another study
observed a slight increase of the MMP2 activity in hypertri-
glyceridemic men after FO supplementation [86]. Further
studies are needed to clarify these discrepancies and the
function of n-3 PUFAs in the regulation of MMPs with re-
gard to potential cardioprotective effects.
Strengths and limitations
The methodological approach of this study was carefully
elaborated. The use of whole blood for RNA isolation is ad-
vantageous in view of the easy sample collection and the
prevention of altered gene expression patterns, which is a
potential risk of cell fractionation steps [30]. In addition,
the pooling of RNA samples reduces inter-individual vari-
ation, enabling one to focus on the effects of FOsupplementation on the population level in contrast to an
individual level [87]. However, the approach of sample
pooling provides several limitations, primarily the reduction
of statistical power. Finally, oxidative damage and oxidative
stress markers were not analysed in this study, which com-
plicates the evaluation of the antioxidative effects.Conclusions
In conclusion, this study showed indications of the antioxi-
dative potential of n-3 PUFAs, especially in dyslipidemic
subjects. FO supplementation resulted in an increased ex-
pression of glutathione synthesis-related genes, an up-
regulation of antioxidative enzymes, such as CAT and
HMOX2, and a reduced expression of MMPs and several
CYPs. Interestingly, CYP1A2 was up-regulated in dyslipi-
demic subjects, suggesting an increased formation of n-3
epoxides. Taken together, these results indicate that n-3
PUFAs may have numerous different possibilities to reduce
oxidative stress. It appears that n-3 PUFAs not only up-
regulates antioxidative enzymes, but rather induces a spe-
cific interplay of differential regulations to generate an opti-
mal balance of the oxidative status. Although the molecular
mechanisms by which n-3 PUFAs mediate potential antiox-
idative effects cannot be clarified here, we hypothesise an
involvement of PPARs. In vitro studies with human hepato-
cytes and pancreatic ß-cells have demonstrated an activa-
tion of PPAR-α or -γ by n-3 PUFAs, which resulted in an
increased expression of CAT, as well as antioxidative effects
[88,89]. Beside CAT, HMOX-1 has also been demonstrated
as a target gene of PPAR [90]. Moreover, an increased ex-
pression of antioxidative genes could result in reduced oxi-
dative stress, which further influences stress-activated
pathways (MAPK and NFkB pathways), as well as other
stress-related genes such as MMPs. However, studies ana-
lysing the expression of antioxidative enzymes, oxidative
signalling processes and metabolic outcomes are needed to
clarify the exact role of n-3 PUFAs within the antioxidative
defence system.Availability of supporting data
The data sets supporting the results of this article are
included within the article.Additional file
Additional file 1: Regulated genes within stress-activated pathways.
Genes, which were regulated after four hours (t4h), one week (t1) and
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regulated genes within mitogen-activated protein kinase (MAPK)
signalling pathway, nuclear factor kappa b (NFkB) pathway and oxidative
stress pathway were displayed.
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